ClinicalTrials.gg
CompletedNCT00477659Updated Nov 10, 2021Results posted

Neural Correlates In Mild Alzheimer's Disease

A Phase 4 interventional study of Donepezil hydrochloride in Alzheimer's Disease, sponsored by Eisai Inc.. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-11-10.

Sponsored by Eisai Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
56th of 58
14 · median 79
Started
2007
with 4 others
Phase 4
20 of 60
none open now
Registered
16th of 60
by date
Lead sponsor
9 of 60
Eisai Inc.

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 56th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2007, is one of 20 in phase 4, and was the 16th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The objective of this study was to identify neural correlates of cognitive improvement after 3 months of donepezil hydrochloride treatment using either or both of two functional magnetic resonance imaging (fMRI) measures - the functional Hippocampus Connectivity Index (HCI) and Cerebral Blood Flow (CBF) Perfusion; in the Medial Temporal Lobe (MTL) network in subjects in the early stage of Alzheimer's Disease (AD).

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Functional magnetic resonance imaging examination
  • Alzheimer's Disease
  • Donepezil hydrochloride
  • Aricept
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, aged 50 and older with mild Alzheimer's disease ( scores of 20 to 30 are allowed).
  • Diagnostic evidence of Alzheimer's disease.
  • Previous use of cholinesterase inhibitors (other than Aricept) and memantine allowed.

Exclusion criteria

Exclusion Criteria:

  • Prior use of Aricept, pacemakers and insulin dependent diabetes are not allowed.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Donepezil hydrochloride

    Drug: Donepezil hydrochloride

Interventions

  • Donepezil hydrochloride 5 mg per day orally, once daily for 4 weeks, followed by 10 mg per day (two 5-mg tablets) for 8 weeks

    Also known as: E2020, Aricept

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI)

    All neuroimaging procedures were performed on a research-dedicated GE 3.0 Tesla whole-body Excite scanner with 8-channel phase-array head coil. Resting-state functional magnetic resonance imaging (fMRI) of the medial temporal lobe (MTL) was performed. The functional HCI was derived from the MTL network using a data driven approach corresponding voxel time courses from the fMR images were processed to extract low frequency fluctuations. Functional connectivity was quantified by calculating the cross-correlation of each voxel time course in the hippocampus to all voxel time courses of the whole brain and the mean of absolute cross-correlation coefficients between a hippocampus voxel to the whole-brain voxels. HCI was then calculated as the average of all hippocampus cross-correlation coefficients. Change from baseline (CFB) was calculated using the CBF-Perfusion Processing Method. A positive change from baseline for HCI indicates improved function.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline at Week 12 in Alzheimer's Disease Assessment Scale - Cognitive Scale (ADAS)-Cog Score

    The ADAS-cog is a 13-item performance-based test that examines selected aspects of cognition including memory, orientation, attention, reasoning, language, and praxis. Total score ranges from 0 to 70 with higher scores indicating greater cognitive impairment. A decrease from baseline indicates improved cognitive function. The ADAS-cog was administered by a trained individual unaware of adverse events reported during this trial.

    Time frame: Baseline and Week 12

  2. Change From Baseline at Week 12 in Mini-Mental State Examination (MMSE) Score

    MMSE was a 11-item scale to measure cognitive status where a higher score indicated better cognitive state. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. The mean change was analyzed by Wilcoxon's signed rank test.

    Time frame: Baseline and Week 12

  3. Change From Baseline at Week 12 in the Instrumental Activities of Daily Living (IADL) Assessment Score

    IADL Scale measures 7 areas of more complex activities required for optimal independent functioning, as reported by the caregiver. The scoring indicates whether the participant was completely independent (3), requires assistance (2), or is dependent (1) for the performance of each activity. A summary score ranges from 7 (high function, independent) to 21 (low function, dependent). The mean change was analyzed by Wilcoxon's signed rank test. A decrease from Baseline to Week 12 indicates improved function.

    Time frame: Baseline and Week 12

  4. Change From Baseline at Week 12 in the Neuropsychiatric Inventory (NPI) Score

    NPI was a 12-item caregiver-based assessment of behavioral disturbances commonly occurring in participants with AD. NPI includes 12 sections which are Delusions, Hallucinations, Agitation, Depression, Anxiety, Euphoria, Apathy, Disinhibition, Irritability, Aberrant motor behavior, Night-time behaviors and Appetite and eating disorders. The score of each section ranges from 0 to 12, and higher score means higher severity and frequency of the neuropsychiatric disturbances. The mean change was analyzed by Wilcoxon's signed rank test.

    Time frame: Baseline and Week 12

07

Results

Posted Nov 10, 2021

Participant flow

Participants took part in this study at one investigative site in the United States from 23 July 2007 to 15 August 2008.

Participant flow — Overall Study
MilestoneDonepezil Hydrochloride
Started14
Completed14
Not completed0

Outcome measures

PrimaryPercent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI)

All neuroimaging procedures were performed on a research-dedicated GE 3.0 Tesla whole-body Excite scanner with 8-channel phase-array head coil. Resting-state functional magnetic resonance imaging (fMRI) of the medial temporal lobe (MTL) was performed. The functional HCI was derived from the MTL network using a data driven approach corresponding voxel time courses from the fMR images were processed to extract low frequency fluctuations. Functional connectivity was quantified by calculating the cross-correlation of each voxel time course in the hippocampus to all voxel time courses of the whole brain and the mean of absolute cross-correlation coefficients between a hippocampus voxel to the whole-brain voxels. HCI was then calculated as the average of all hippocampus cross-correlation coefficients. Change from baseline (CFB) was calculated using the CBF-Perfusion Processing Method. A positive change from baseline for HCI indicates improved function.

Time frame:
Week 12
Reported as:
Mean · percent change
Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI)
percent changeDonepezil Hydrochloride
Percent Change From Baseline to Week 12 Based on Hippocampus Connectivity Index (HCI)7.47 ± 17.23
SecondaryChange From Baseline at Week 12 in Alzheimer's Disease Assessment Scale - Cognitive Scale (ADAS)-Cog Score

The ADAS-cog is a 13-item performance-based test that examines selected aspects of cognition including memory, orientation, attention, reasoning, language, and praxis. Total score ranges from 0 to 70 with higher scores indicating greater cognitive impairment. A decrease from baseline indicates improved cognitive function. The ADAS-cog was administered by a trained individual unaware of adverse events reported during this trial.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline at Week 12 in Alzheimer's Disease Assessment Scale - Cognitive Scale (ADAS)-Cog Score
score on a scaleDonepezil Hydrochloride
Baseline12.0 ± 4.85
Change at Week 12-1.6 ± 2.81
SecondaryChange From Baseline at Week 12 in Mini-Mental State Examination (MMSE) Score

MMSE was a 11-item scale to measure cognitive status where a higher score indicated better cognitive state. The score ranged from 0 to 30, with a higher score indicating better function. A positive change score indicated improvement from baseline. The mean change was analyzed by Wilcoxon's signed rank test.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline at Week 12 in Mini-Mental State Examination (MMSE) Score
score on a scaleDonepezil Hydrochloride
Baseline26.1 ± 1.33
Change at Week 120.1 ± 2.70
SecondaryChange From Baseline at Week 12 in the Instrumental Activities of Daily Living (IADL) Assessment Score

IADL Scale measures 7 areas of more complex activities required for optimal independent functioning, as reported by the caregiver. The scoring indicates whether the participant was completely independent (3), requires assistance (2), or is dependent (1) for the performance of each activity. A summary score ranges from 7 (high function, independent) to 21 (low function, dependent). The mean change was analyzed by Wilcoxon's signed rank test. A decrease from Baseline to Week 12 indicates improved function.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline at Week 12 in the Instrumental Activities of Daily Living (IADL) Assessment Score
score on a scaleDonepezil Hydrochloride
Baseline13.1 ± 3.71
Change at Week 12-0.3 ± 2.70
SecondaryChange From Baseline at Week 12 in the Neuropsychiatric Inventory (NPI) Score

NPI was a 12-item caregiver-based assessment of behavioral disturbances commonly occurring in participants with AD. NPI includes 12 sections which are Delusions, Hallucinations, Agitation, Depression, Anxiety, Euphoria, Apathy, Disinhibition, Irritability, Aberrant motor behavior, Night-time behaviors and Appetite and eating disorders. The score of each section ranges from 0 to 12, and higher score means higher severity and frequency of the neuropsychiatric disturbances. The mean change was analyzed by Wilcoxon's signed rank test.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Change From Baseline at Week 12 in the Neuropsychiatric Inventory (NPI) Score
score on a scaleDonepezil Hydrochloride
Baseline9.2 ± 10.00
Change at Week 12-3.4 ± 11.25

Adverse events

Collected over All adverse events were collected from first dose of study drug (Baseline) up to 30 days after last dose of study drug (approximately up to 12 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Donepezil Hydrochloride0/14 (0%)0/14 (0%)11/14 (78.6%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventDonepezil Hydrochloride
DiarrheaGastrointestinal disorders2/14
RhinorrheaRespiratory, thoracic and mediastinal disorders2/14
Decreased appetiteMetabolism and nutrition disorders1/14
Weight lossMetabolism and nutrition disorders1/14
Ear painEar and labyrinth disorders1/14
Eye painEye disorders1/14
Vision blurredEye disorders1/14
Feces discoloredGastrointestinal disorders1/14
FlatulenceGastrointestinal disorders1/14
Stomach discomfortGastrointestinal disorders1/14

Baseline characteristics

The Intent-to-Treat (ITT) set included all participants who received at least one dose of study medication, had a baseline efficacy evaluation, and had at least one post-baseline efficacy evaluation.

Age, Categorical
Age, Categorical(Participants)Donepezil
<=18 years0
Between 18 and 65 years0
>=65 years14
Age, Continuous
Age, Continuous(years)Donepezil
Mean77.6 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Donepezil
Female5
Male9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Donepezil
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Donepezil
United States14
08

Study locations

1 site
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in Aug 2008, 12 months.

Results were first posted in Nov 2021, 13 years 2 months after primary completion.

Of 41 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2007
First posted
May 24, 2007
StartActual
Jul 23, 2007
Primary completionActual
Aug 15, 2008
CompletionActual
Aug 15, 2008
Results first posted
Nov 10, 2021
Last update
Nov 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00477659
Lead sponsor
Eisai Inc.
Collaborators
Pfizer
Responsible party
Sponsor
First posted
May 24, 2007
Start date
Jul 23, 2007
Primary completion
Aug 15, 2008
Completion
Aug 15, 2008
Results posted
Nov 10, 2021
Last update
Nov 10, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion